Jefferies initiated coverage on Rapport Therapeutics with a new price target
$RAPP
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2024 | Buy | TD Cowen | |
| 7/2/2024 | $35.00 | Buy | Jefferies |
| 7/2/2024 | $35.00 | Buy | Stifel |
10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is
TD Cowen analyst Joseph Thome initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating.
Jefferies analyst Andrew Tsai initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $35.
Stifel analyst Paul Matteis initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $35.
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting, taking place December 6-10, 2024, in Los Angeles. Using analysis from an open-label, long-term treatment study of the RNS® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal electrographic activity) and clinically meaningful reduction ( 50
Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows: The Stifel Healthcare Conference in New York CityMonday, November 18, 2024, at 1:15pm ET The Jefferies London Healthcare ConferenceWednesday, November 20, 2024, at 4:00pm GMT/11am ET Interested parties may access the live and archived webcasts under the "Investors" section of the company's website
TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy
Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
Stifel initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)